Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. research hub

KANDOVA - A two-part Phase Ib/IIa study to evaluate the safety and tolerability of KAND567, in combination with carboplatin therapy, and to determine the Recommended Phase II Dose (RPIID) of KAND567. An open-label, multicenter dose escalation study with an expansion cohort in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

This study is looking at a new medicine called KAND567, given alongside standard carboplatin chemotherapy, for women with ovarian, fallopian tube, or primary peritoneal cancer that has come back. It aims to see how safe it is and find the best dose.